Downloading...
Download

Bigpharma

BMY- a large cap pharm loosing market cap SHORTBMY is here on the daily chart. The double top and death cross of the EMA moving averages makes for a strong candidate to short with shares or take put options. A comparsion of the most recent earnings report with the previous one sixty days earlier tells most of the story. The dual time frame RSI indicator shows ongoing wekaness. I will short BMY here and take some call options as well. I am in LLY long in a big position. This will be a race in opposite directions for two large cap pharmaceuticals.
NYSE:BMYShort
by AwesomeAvani
Pharmaceutical Giants Stocks: Macro Fib SchematicsThe biggest pharma giants are easy to recognize. Johnson and Johnson, Pfizer, Moderna, Merck & Co, Danaher Corp, Thermo Fisher Scientific. All medications and pharmaceutical drugs come out of these drug corporations. Lab equipment, medical research, vaccines, and other life science developments come out of these conglomerate pharma giants. Support and Resistance is clear with these schematics. All clusters are laid over appropriately.
NASDAQ:MRNA
by MichaelBsul
LLY rides its success against obesity and diabetes LONGLLY shown on a daily chart has doubled in the past year with the introduction of new FDA approved drugs into the market. It has but out a series of favorable earnings reports with optimistic realistic guidance and glowing analysts' forecasts. It has done so without any volume pumps and just keeps grinding higher. This is because it is in the shadows of big technology stocks. Revenues consistently beat analysts' forecasts quarter after quarter. Institutions add small lots trying to preserve the price for future buys without any run-ups. I have done the same thing and I will continue to do so. While day trading biotechnology penny stocks, LLY along with UNH, PFE, and AZN is where the profits are parked for growth and compounding.
NYSE:LLYLong
by AwesomeAvani
1
LLY Earnings Play LONG ( Flat Bottom Triangle Breakout)My analysis is on the 2H. I am uniquely qualified in my fundamental analysis. This is a one day until earnings. My thesis is the earnings will stimulate what will be a breakout from a flat bottom triangle. I will buy one share of stock. I will spend a similar amount on call options striking $460 expiring August 11th. I see LLY as surging while PFE is a bit challenged with the fall off in Covid vaccine work. If you find this idea interesting and might appreciate my ideas as to a stop loss and targets, leave a comment. Like and subscribe. Trade well !
NYSE:LLYLong
by AwesomeAvani
1
Profits Over Patients: The Morally Complex Realm of Big PharmaThis strategy dissects the dual nature of big pharmaceutical firms like Johnson & Johnson, Pfizer, Moderna, and Merck & Co viewed through base Fibonacci Extension Clustering. Despite big pharma's significant contributions to healthcare, these firms have benefited from questionable practices, including price manipulation and exploiting addictions . Price manipulation is a notorious strategy where companies arbitrarily hike drug prices, often without any significant improvements in their efficacy. "Big Pharma" has faced backlash for allegedly contributing to the opioid crisis . By aggressively marketing highly addictive pain medications , they may have exacerbated a public health catastrophe, leading to thousands of deaths annually. Such practices illuminate the immoral landscape of the pharmaceutical industry. While these firms play a vital role in global healthcare, their business tactics often prioritize profits over patients, demanding a closer scrutiny of this sector's ethics. 1. Johnson & Johnson (JNJ): Around $440 billion 2. Pfizer Inc. (PFE): Around $240 billion 3. Moderna Inc. (MRNA): Around $110 billion 4. Merck & Co., Inc. (MRK): Around $200 billion TOTAL = 1 Trillion
NASDAQ:MRNA
by MichaelBsul
LABU Triple Leveraged Biotech Sector ETFOn the 4H Chart LABU is trending up since March 27th. Last week there was a small pullback which was met with more buying activity. On the volume indicator, the volume now is approximately 10X day by day compared with March's averages. It is this buying that is driving the bullish momentum. Small-cap speculative biotech companies are in a growth mode right now no matter adverse economic conditions for those yet to have any earnings. Big pharma is more concerned about federal attempts to further regulate prices than the economy. On the volume profile, price has ascended to above the high volume trading area on the strength of buyer interest propelling the momentum. Overall, this looks to be a decent long trade. The target is $ 9.00 the YTD high back in February.
AMEX:LABULong
by AwesomeAvani
PFE Large Cap Pharma increased its dividendPFE just raised its dividend On the chart it has been trending downward as shown also by a down sloping anchored VWAP bands. Price is currently sitting at long term support and two standard deviations below VWAP. It appears to be ready to reverse from the deep undervalued area. In confirmation, teh voume indicator shows moderate increased relative volume compared with March. I see this as a good opportunity to enter a swing long trade or investment. PFE has its increased dividend as a hint to shareholders of increasing earnings also with the next generation of COVID vaccines in the pipeline along with a diversified line of other products. The only thing that will slow PFE down in federal legislation to limit the retail MSRP prices of its products to all consumers including those with no insurance and commercial coverage outside federal programs. PFE is solid as a rock. I see the buy signal.
NYSE:PFELong
by AwesomeAvani
2
Pfizer and Ghislaine and JeffHavin a look is all. Such a move in PFE, worth reflecting on what Big Pharma really is. Do you know why USA is only country that allows TV commercials of Big Pharma? Any other countries? Why so many connections to FDA? Why so many connections to the Israelis and regular attendees at Bilderberg. People will dismiss these connections as tinfoil then drool over a vaguely worded FED statement, trusting the bots to decipher bias. People will place earnings trades based on economic data. And these larger Bilderbeg and WEF groups are looking at data from sky high macro view. From a practical perspective, some of them think they are just solving problems.
NYSE:PFEShort
by allthemoneys
5 Stocks we are looking into for the Covid-19 VaccineFirst off, please don't take anything I say seriously or as financial advice. As always, this is on an opinion based basis. That being said, let me get into my insights. There was rumors that AstraZeneca wanted to merge w/ Gilead. However, it looks like this may not happen. Until, the books are closed don't get your hopes up, but invest as if you expect something like this to go down. As far as stocks such as Pfizer, Pfizer so far is greatly underrated in terms of growth potential during the vaccine trials period, and likely because of that it is due for a bullish run quite soon. NVAX and Moderna, I believe already have the most stable growth potential given the logarithmic curves. These 5 stocks may be quite interesting to look at given all these giants from Pfizer to Moderna to Gilead are working on being the forefront of the expected Covid19 vaccine delivery. If this is a huge revenue booster, that means obvious profit turn over potential. Also, it is likely better for a buy entry previous to August, September, and the winter when hype may start increasing. Lots of the excitement have very recently slowed down, and you likely don't want to wait for the hype if you do long term holds.
NYSE:PFELong
by gamer456148
1